Published in Ann Surg Oncol on July 06, 2012
Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol (2013) 1.20
Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone? World J Gastroenterol (2014) 0.97
Liver-directed therapies in metastatic colorectal cancer. J Gastrointest Oncol (2014) 0.97
Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol (2013) 0.93
The association between preoperative chemotherapy and the prevalence of hepatic steatosis in hepatectomy for metastatic colorectal cancer. Arq Bras Cir Dig (2014) 0.84
Reductions in post-hepatectomy liver failure and related mortality after implementation of the LiMAx algorithm in preoperative work-up: a single-centre analysis of 1170 hepatectomies of one or more segments. HPB (Oxford) (2015) 0.79
Sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy. Clin Mol Hepatol (2014) 0.78
Potential of MR histogram analyses for prediction of response to chemotherapy in patients with colorectal hepatic metastases. Eur Radiol (2015) 0.78
Liver angulometry: a simple method to estimate liver volume and ratios. HPB (Oxford) (2013) 0.76
Portal vein embolization effect on colorectal cancer liver metastasis progression: Lessons learned. World J Clin Oncol (2015) 0.76
Oxaliplatin-based chemotherapy induces extravasated platelet aggregation in the liver. Mol Clin Oncol (2015) 0.76
Hepatic Sinusoidal Obstruction Syndrome Induced by Non-transplant Chemotherapy for Non-Hodgkin Lymphoma. Intern Med (2017) 0.75
Preoperative chemotherapy for locally advanced resectable colon cancer - a new treatment paradigm in colon cancer? Ann Transl Med (2013) 0.75
Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis. BMC Cancer (2017) 0.75
A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer. Chin J Cancer Res (2016) 0.75
Loss of chromosome 4 correlates with better long-term survival and lower relapse rate after R0-resection of colorectal liver metastases. J Cancer Res Clin Oncol (2013) 0.75
Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis. Langenbecks Arch Surg (2017) 0.75
Effect of age on the development of chemotherapy-associated liver injury in colorectal cancer liver metastasis. Mol Clin Oncol (2017) 0.75
Sinusoidal obstruction syndrome in the animal model: influence on liver surgery. Langenbecks Arch Surg (2016) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 55.37
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer (2010) 10.61
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 9.36
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol (2009) 5.42
Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg (2004) 5.10
Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol (2004) 4.78
Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg (1996) 4.41
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol (2005) 3.88
Factors influencing the natural history of colorectal liver metastases. Lancet (1994) 3.61
Epidemiology and management of liver metastases from colorectal cancer. Ann Surg (2006) 3.37
Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol (2001) 3.28
Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology (1997) 3.28
Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg (2006) 3.05
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol (2006) 2.71
Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol (2008) 2.52
Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg (2012) 2.49
Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg (2007) 2.40
Long-term survival and disease recurrence following portal vein embolisation prior to major hepatectomy for colorectal metastases. Ann Surg Oncol (2009) 2.27
Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis (2002) 2.17
Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer (2007) 2.12
Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg (2008) 2.10
Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol (2006) 1.90
Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg (2008) 1.85
Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg (2010) 1.85
A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg (2006) 1.81
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol (2010) 1.80
Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. Arch Surg (2007) 1.63
Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. Surgery (2010) 1.56
Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg (2009) 1.56
Preoperative chemotherapy and the outcome of liver resection for colorectal metastases. World J Surg (2007) 1.52
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol (2007) 1.49
Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology (2010) 1.48
Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg (2007) 1.46
Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol (2010) 1.42
Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol (2010) 1.36
The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford) (2010) 1.30
Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol (2007) 1.22
The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol (2009) 1.21
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol (2008) 1.20
Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev (2005) 1.20
Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis. Br J Surg (2007) 1.19
Modern multimodality approach to hepatic colorectal metastases: solutions and controversies. Surg Oncol (2007) 1.18
Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis (2011) 1.18
Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg (2010) 1.18
Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer (2007) 1.16
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol (2009) 1.13
Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol (2009) 1.11
Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol (2008) 1.11
Irinotecan pharmacogenomics. Pharmacogenomics (2010) 1.07
The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. Virchows Arch (2007) 1.04
Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. Am J Surg Pathol (2010) 1.04
Systemic chemotherapy and its implications for resection of colorectal liver metastasis. Surg Oncol (2009) 1.02
Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol (2007) 1.02
Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg (2006) 0.99
Sinusoidal obstruction syndrome. Clin Liver Dis (2010) 0.97
Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. J Surg Oncol (2007) 0.96
Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. Br J Radiol (2006) 0.95
Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing. Ann Surg Oncol (2011) 0.95
Making unresectable hepatic colorectal metastases resectable--does it work? Semin Oncol (2005) 0.94
Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. J Am Coll Surg (2010) 0.90
Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg (2010) 0.90
Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology. Ann Diagn Pathol (2010) 0.88
Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg (2006) 0.87
Accuracy of liver-specific magnetic resonance imaging as a predictor of chemotherapy-associated hepatic cellular injury prior to liver resection. Eur J Surg Oncol (2009) 0.87
Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg (2007) 0.87
Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases. J Gastrointest Surg (2011) 0.86
Prognostic value of the monoethylglycinexylidide (MEGX)-test prior to liver resection. Hepatogastroenterology (2008) 0.85
Quantitative assessment of hepatic function and its relevance to the liver surgeon. J Gastrointest Surg (2008) 0.85
Chemotherapy in metastatic colorectal cancer. Surg Oncol (2007) 0.84
Sinusoidal obstruction syndrome compromises liver regeneration in patients undergoing two-stage hepatectomy with portal vein embolization. Surg Today (2010) 0.83
A critical appraisal of the role of neoadjuvant chemotherapy for colorectal liver metastases: a case-controlled study. Ann Surg Oncol (2007) 0.82
Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients. Int J Clin Oncol (2010) 0.80
Neoadjuvant chemotherapy does not increase postoperative complication rate after resection of colorectal liver metastases. Eur J Surg Oncol (2005) 0.78
[Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases]. Cir Esp (2010) 0.77
Preoperative systemic chemotherapy does not modify strategy of liver resection. Hepatogastroenterology (2006) 0.77
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology (2008) 3.60
Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol (2006) 2.88
Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nat Med (2012) 2.28
Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. Hepatology (2007) 2.21
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut (2010) 2.20
Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest (2007) 2.01
Liver fibrosis. Biochem J (2008) 1.97
Current practices of donor pancreas allocation in the UK: future implications for pancreas and islet transplantation. Transpl Int (2005) 1.55
Human liver stem cells originate from the canals of Hering. Hepatology (2009) 1.46
Stimulating healthy tissue regeneration by targeting the 5-HT₂B receptor in chronic liver disease. Nat Med (2011) 1.45
Submaximal cardiopulmonary exercise testing predicts complications and hospital length of stay in patients undergoing major elective surgery. Ann Surg (2010) 1.32
Chronic renal allograft dysfunction: the role of T cell-mediated tubular epithelial to mesenchymal cell transition. J Am Soc Nephrol (2004) 1.25
Non-alcoholic fatty liver disease in older people. Gerontology (2009) 1.22
Quality really matters: the need to improve specimen quality in biomedical research. Histopathology (2012) 1.14
Alcoholic liver disease. Semin Diagn Pathol (2007) 1.12
Fibrosis and cirrhosis reversibility - molecular mechanisms. Clin Liver Dis (2008) 1.10
The c-Rel subunit of nuclear factor-kappaB regulates murine liver inflammation, wound-healing, and hepatocyte proliferation. Hepatology (2010) 1.09
Routine intraoperative stenting for renal transplant recipients. Transplantation (2005) 1.09
A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer (2009) 1.08
Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J Gen Virol (2004) 1.08
Non-heart beating donor kidneys with delayed graft function have superior graft survival compared with conventional heart-beating donor kidneys that develop delayed graft function. Am J Transplant (2003) 1.02
The diffuse stellate cell system. J Mol Histol (2007) 1.02
Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol (2013) 0.98
The surgical management of peritoneal dialysis catheters. Ann R Coll Surg Engl (2004) 0.96
Histone methyltransferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation. Hepatology (2012) 0.95
Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. Hepatology (2012) 0.94
NF-kappaB is a critical regulator of the survival of rodent and human hepatic myofibroblasts. J Hepatol (2008) 0.92
Long-term renal function in kidneys from non-heart-beating donors: A single-center experience. Transplantation (2002) 0.91
Metastatic breast carcinoma presenting as acute liver failure and portal hypertension. Am J Gastroenterol (2002) 0.90
Primary hepatocellular carcinoma of the pancreas: a case report and review of the heterogeneous group of pancreatic hepatoid carcinomas. Histopathology (2012) 0.90
Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology (2013) 0.89
Quality really matters: the need to improve specimen quality in biomedical research. J Pathol (2012) 0.89
Routine intraoperative ureteric stenting for kidney transplant recipients. Cochrane Database Syst Rev (2013) 0.89
Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation (2011) 0.89
Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation (2006) 0.88
The PXR is a drug target for chronic inflammatory liver disease. J Steroid Biochem Mol Biol (2010) 0.88
Inhibition of RelA-Ser536 phosphorylation by a competing peptide reduces mouse liver fibrosis without blocking the innate immune response. Hepatology (2013) 0.86
Incidental pT2-T3 gallbladder cancer after a cholecystectomy: outcome of staging at 3 months prior to a radical resection. HPB (Oxford) (2013) 0.86
Graft function after kidney transplantation from non-heartbeating donors according to maastricht category. J Urol (2004) 0.85
Identification of a neuronal transcription factor network involved in medulloblastoma development. Acta Neuropathol Commun (2013) 0.85
Role of EUS/EUS-guided FNA in the management of proximal biliary strictures. Hepatogastroenterology (2012) 0.84
Pathology of the liver sinusoids. Histopathology (2014) 0.83
How to improve the quality of kidneys from non-heart-beating donors: a randomised controlled trial of thrombolysis in non-heart-beating donors. Transplantation (2003) 0.83
Investigation of a mechanism for accelerated breakdown of immune tolerance to the primary biliary cirrhosis-associated autoantigen, pyruvate dehydrogenase complex. Lab Invest (2002) 0.83
T cell-mediated biliary epithelial-to-mesenchymal transition in liver allograft rejection. Liver Transpl (2010) 0.82
An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury. HPB (Oxford) (2012) 0.82
Bacterial motif DNA as an adjuvant for the breakdown of immune self-tolerance to pyruvate dehydrogenase complex. Hepatology (2002) 0.82
Development of a robust protocol for gene expression analysis using formalin-fixed, paraffin-embedded liver transplant biopsy specimens. J Clin Pathol (2013) 0.82
Endoscopic ultrasound in patients with normal liver blood tests and unexplained dilatation of common bile duct and or pancreatic duct. Scand J Gastroenterol (2014) 0.82
Disrupted pancreatic exocrine differentiation and malabsorption in response to chronic elevated systemic glucocorticoid. Am J Pathol (2010) 0.82
Color coding of sutures in laparoscopic perforated duodenal ulcer: a new concept. Surg Laparosc Endosc Percutan Tech (2002) 0.81
Laparoscopic liver resection for hepatic adenoma in pregnancy. J Clin Gastroenterol (2011) 0.81
White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers. BMC Gastroenterol (2013) 0.81
Cholestasis secondary to anabolic steroid use in young men. BMJ (2012) 0.80
Utility of B-13 progenitor-derived hepatocytes in hepatotoxicity and genotoxicity studies. Toxicol Sci (2013) 0.80
Laparoscopic liver resection: is there a learning curve? Dig Surg (2012) 0.80
Covalent modification as a mechanism for the breakdown of immune tolerance to pyruvate dehydrogenase complex in the mouse. Hepatology (2004) 0.79
N-acetylcysteine administration does not improve patient outcome after liver resection. HPB (Oxford) (2013) 0.79
Clinical but not histological factors predict long-term prognosis in patients with histologically advanced non-decompensated alcoholic liver disease. Liver Int (2013) 0.79
Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser. J Clin Virol (2013) 0.79
Phospholipase D and extracellular signal-regulated kinase in hepatic stellate cells: effects of platelet-derived growth factor and extracellular nucleotides. Am J Physiol Gastrointest Liver Physiol (2006) 0.78
Pancreatic islet cell transplantation: progress in the clinical setting. Treat Endocrinol (2003) 0.78
Do tissue damage biomarkers used to assess machine-perfused NHBD kidneys predict long-term renal function post-transplant? Clin Chim Acta (2003) 0.78
A cadaver lab training facility to facilitate laparoscopic liver resection. Surg Laparosc Endosc Percutan Tech (2014) 0.77
Ontogeny of human intrahepatic innervation. Virchows Arch (2008) 0.77
Granular cell tumor as an unusual cause of obstruction at the hepatic hilum: report of a case. Surg Today (2006) 0.77
Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients. Cochrane Database Syst Rev (2014) 0.76
Epithelial to mesenchymal transition in primary sclerosing cholangitis. Liver Int (2008) 0.76
Endoscopic botulinum toxin injection for the treatment of diabetic gastropathy in pancreas and islet-cell transplant patients. Exp Clin Transplant (2012) 0.76
The specificity of liver inflammation in mouse models of primary biliary cirrhosis. Hepatology (2008) 0.76
ABO incompatible liver transplantation: a case of immediate need. Transpl Int (2007) 0.76
Use of a multilayered stent for the treatment of hepatic artery pseudoaneurysm after liver transplantation. Cardiovasc Intervent Radiol (2012) 0.75
Indwelling stents after ureteroscopy. BMJ (2007) 0.75
A liver fibrosis cocktail? Psoriasis, methotrexate and genetic hemochromatosis. BMC Dermatol (2005) 0.75
Abrikosoff's Tumor and the Hepatobiliary System: A Curiosa Revisited. Gastroenterol Hepatol (N Y) (2010) 0.75
Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation (2007) 0.75
Interleukin 2 receptor blockers may directly inhibit lymphocyte mediated ischaemia reperfusion injury. Transpl Int (2005) 0.75
Antibody induction versus corticosteroid induction for liver transplant recipients. Cochrane Database Syst Rev (2014) 0.75
Preemptive Appendicectomy at the Time of Pancreas Transplantation: Is It Necessary? Exp Clin Transplant (2019) 0.75
Dual ipsilateral renal transplantation from a non-heart-beating donor. Ann R Coll Surg Engl (2005) 0.75
Tempting liver fibrosis? Long-term psoriatic methotrexate therapy and heterozygous alpha1-antitrypsin deficiency. Dermatology (2006) 0.75
Successful management of necrotizing pancreatitis by percutaneous necrosectomy after orthotopic liver transplant for paracetamol induced acute liver failure: a case report. Exp Clin Transplant (2009) 0.75
Extracorporeal membrane oxygenation for resuscitation of deceased cardiac donor livers for hepatocyte isolation. J Surg Res (2013) 0.75
Laparoscopic splenic biopsy--porcine to human studies--using a fibrin sealant technique. Surg Laparosc Endosc Percutan Tech (2013) 0.75
Annual review issue: surgical pathology of 21st century medicine. Histopathology (2017) 0.75
Columnar Metaplasia in the Esophageal Remnant After Esophagectomy: A Common Occurrence and a Valuable Insight Into the Development of Barrett Esophagus. Ann Surg (2016) 0.75
National Organ Retrieval Imaging System: results of the pilot study. Transpl Int (2008) 0.75
Idiopathic pseudomembranous colitis limited to the right colon: a change from Clostridium difficile. Int J Colorectal Dis (2008) 0.75
Hypertrophy in the contralateral lobe post-selective internal radiation therapy. Future Oncol (2014) 0.75
Endovascular management of arterial conduit pseudoaneurysm after liver transplantation: a report of two cases. Transplantation (2005) 0.75